These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 26347494)
1. Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C. White EC; Goldman K; Aleshin A; Lien WW; Rao AR Radiother Oncol; 2015 Nov; 117(2):240-5. PubMed ID: 26347494 [TBL] [Abstract][Full Text] [Related]
2. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. Wo JY; Plastaras JP; Metz JM; Jiang W; Yeap BY; Drapek LC; Adams J; Baglini C; Ryan DP; Murphy JE; Parikh AR; Allen JN; Clark JW; Blaszkowsky LS; DeLaney TF; Ben-Josef E; Hong TS Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):90-95. PubMed ID: 31128146 [TBL] [Abstract][Full Text] [Related]
3. A population-based analysis of the impact of 1 vs. 2 doses of mitomycin on patterns of failure of anal cancer patients treated with concurrent chemoradiotherapy. Joseph K; Al Habsi Z; Abraham A; Elangovan A; Ghosh S; Pham T; Shreekumar D; Ramji Z; Paulson K; Tankel K; Usmani N; Severin D; Schiller D; Wong C; Mulder K; Karachiwala H; Doll C; King K; Nijjar T Radiother Oncol; 2024 Jul; 196():110219. PubMed ID: 38479443 [TBL] [Abstract][Full Text] [Related]
5. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585 [TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664 [TBL] [Abstract][Full Text] [Related]
7. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707 [TBL] [Abstract][Full Text] [Related]
8. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal. Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173 [TBL] [Abstract][Full Text] [Related]
9. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial. Glynne-Jones R; Kadalayil L; Meadows HM; Cunningham D; Samuel L; Geh JI; Lowdell C; James R; Beare S; Begum R; Ledermann JA; Sebag-Montefiore D; Ann Oncol; 2014 Aug; 25(8):1616-22. PubMed ID: 24827136 [TBL] [Abstract][Full Text] [Related]
10. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724 [TBL] [Abstract][Full Text] [Related]
11. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443 [TBL] [Abstract][Full Text] [Related]
12. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. Flam M; John M; Pajak TF; Petrelli N; Myerson R; Doggett S; Quivey J; Rotman M; Kerman H; Coia L; Murray K J Clin Oncol; 1996 Sep; 14(9):2527-39. PubMed ID: 8823332 [TBL] [Abstract][Full Text] [Related]
13. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. Sebag-Montefiore D; Meadows HM; Cunningham D; Plowman PN; Hurman DC; Davidson N; Grieve R; Levine E; Glynne-Jones R Radiother Oncol; 2012 Aug; 104(2):155-60. PubMed ID: 22857859 [TBL] [Abstract][Full Text] [Related]
14. Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer. Lee IH; Lee SJ; Kang BW; Chae YS; Baek D; Hwang S; Kim HJ; Park SY; Park JS; Choi GS; Kim JC; Kim JG Cancer Chemother Pharmacol; 2016 Dec; 78(6):1263-1267. PubMed ID: 27830320 [TBL] [Abstract][Full Text] [Related]
15. Feasibility and Outcome of Routine Use of Concurrent Chemoradiation in HIV-positive Patients With Squamous Cell Anal Cancer. Leiker AJ; Wang CJ; Sanford NN; Aguilera TA; Karri S; Beg MS; Kazmi SA; Olson C; Matthews JA; Abdelnaby A; Meyer JJ; Folkert MR Am J Clin Oncol; 2020 Oct; 43(10):701-708. PubMed ID: 32694298 [TBL] [Abstract][Full Text] [Related]
16. Review of anal cancer patients at the Ottawa hospital. Abunassar M; Reinders J; Jonker DJ; Asmis T Eur J Surg Oncol; 2015 May; 41(5):653-8. PubMed ID: 25776438 [TBL] [Abstract][Full Text] [Related]
17. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075 [TBL] [Abstract][Full Text] [Related]
18. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease. Fraunholz IB; Haberl A; Klauke S; Gute P; Rödel CM Dis Colon Rectum; 2014 Apr; 57(4):423-31. PubMed ID: 24608297 [TBL] [Abstract][Full Text] [Related]
19. Comparison of Toxicity and Treatment Outcomes in HIV-positive Versus HIV-negative Patients With Squamous Cell Carcinoma of the Anal Canal. White EC; Khodayari B; Erickson KT; Lien WW; Hwang-Graziano J; Rao AR Am J Clin Oncol; 2017 Aug; 40(4):386-392. PubMed ID: 25513996 [TBL] [Abstract][Full Text] [Related]
20. Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer. Joseph K; Nijjar Y; Warkentin H; Schiller D; Tankel K; Usmani N; Severin D; Ghosh S; Syme A; Nijjar T; Mulder K; Doll C; Wong C; Field C Radiother Oncol; 2015 Nov; 117(2):234-9. PubMed ID: 26306677 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]